AU2003281917A1 - Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats - Google Patents

Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats

Info

Publication number
AU2003281917A1
AU2003281917A1 AU2003281917A AU2003281917A AU2003281917A1 AU 2003281917 A1 AU2003281917 A1 AU 2003281917A1 AU 2003281917 A AU2003281917 A AU 2003281917A AU 2003281917 A AU2003281917 A AU 2003281917A AU 2003281917 A1 AU2003281917 A1 AU 2003281917A1
Authority
AU
Australia
Prior art keywords
feline
oncoviruses
cats
infections caused
vaccine against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003281917A
Other languages
English (en)
Other versions
AU2003281917A8 (en
Inventor
Christiane Juhls
Claas Junghans
Detlef Oswald
Matthias Schroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologen AG
Original Assignee
Mologen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen AG filed Critical Mologen AG
Publication of AU2003281917A8 publication Critical patent/AU2003281917A8/xx
Publication of AU2003281917A1 publication Critical patent/AU2003281917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003281917A 2002-09-23 2003-09-19 Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats Abandoned AU2003281917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10244863 2002-09-23
DE10244863.9 2002-09-23
PCT/DE2003/003179 WO2004028562A2 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Publications (2)

Publication Number Publication Date
AU2003281917A8 AU2003281917A8 (en) 2004-04-19
AU2003281917A1 true AU2003281917A1 (en) 2004-04-19

Family

ID=32038184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003281917A Abandoned AU2003281917A1 (en) 2002-09-23 2003-09-19 Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats

Country Status (9)

Country Link
US (1) US7915035B2 (https=)
EP (1) EP1553977B1 (https=)
JP (1) JP4411213B2 (https=)
AT (1) ATE335507T1 (https=)
AU (1) AU2003281917A1 (https=)
DE (2) DE50304603D1 (https=)
DK (1) DK1553977T3 (https=)
ES (1) ES2270120T3 (https=)
WO (1) WO2004028562A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
SMT201900129T1 (it) * 2011-07-20 2019-05-10 Centre Nat Rech Scient Vaccino ricombinante contro il virus della leucemia felina contenente un gene ottimizzato dell'involucro del virus della leucemia felina
CA3080430A1 (en) 2017-11-06 2019-06-13 Intervet International B.V. Feline calicivirus vaccine
JP7731670B2 (ja) * 2017-11-06 2025-09-01 インターベット インターナショナル ベー． フェー． ネコ白血病ウイルスワクチン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
EP1432805B1 (de) * 2001-10-02 2005-05-18 Mologen AG Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose

Also Published As

Publication number Publication date
WO2004028562A3 (de) 2004-06-03
AU2003281917A8 (en) 2004-04-19
WO2004028562A2 (de) 2004-04-08
ES2270120T3 (es) 2007-04-01
EP1553977B1 (de) 2006-08-09
DK1553977T3 (da) 2006-11-27
EP1553977A2 (de) 2005-07-20
DE10393824D2 (de) 2005-08-11
ATE335507T1 (de) 2006-09-15
JP4411213B2 (ja) 2010-02-10
DE50304603D1 (de) 2006-09-21
US7915035B2 (en) 2011-03-29
JP2006511211A (ja) 2006-04-06
US20060240034A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
UA85536C2 (en) Viral antigens
AR042378A2 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de dicho poxvirus para preparar una vacuna eficaz contra la infeccion del virus de inmunodeficiencia felina
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
CY1109675T1 (el) Αντιμικροβιακα πολυπεπτιδια
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
AU2003281917A1 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
ATE543513T1 (de) Anti-coronavirus impfstoff
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
WO2005001029A3 (en) Ancestral viruses and vaccines
HK1046911A1 (zh) 经稳定的病毒外膜蛋白质及其使用
AU8405798A (en) A swine hepatitis e virus and uses thereof
AU686000B2 (en) Infectious peritonitis vaccine
WO2004031209A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
WO2003022883A3 (de) Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems
AU2002341238A1 (en) Diabetic model
DK1196607T3 (da) Antibakterielt chlamysin B-protein, gen kodende derfor samt ekspressionssystem
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
WO2000069886A3 (en) Oligomeric chaperone proteins
WO2005010163A3 (en) Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase